HC Wainwright started coverage on shares of Lipocine Inc. (NASDAQ:LPCN) in a research report sent to investors on Friday morning. The brokerage issued a buy rating and a $25.00 price objective on the specialty pharmaceutical company’s stock.

Separately, Canaccord Genuity reiterated a buy rating and issued a $6.00 target price on shares of Lipocine in a report on Wednesday, August 10th.

Lipocine (NASDAQ:LPCN) traded up 3.33% on Friday, hitting $5.59. 1,398,010 shares of the stock were exchanged. Lipocine has a one year low of $2.51 and a one year high of $14.80. The company’s market cap is $102.06 million. The company’s 50 day moving average price is $3.80 and its 200-day moving average price is $6.52.

Lipocine (NASDAQ:LPCN) last issued its earnings results on Tuesday, August 9th. The specialty pharmaceutical company reported ($0.32) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.37) by $0.05. Equities research analysts predict that Lipocine will post ($1.31) EPS for the current fiscal year.

A number of institutional investors have recently added to or reduced their stakes in LPCN. Carlson Capital L P increased its position in Lipocine by 88.3% in the second quarter. Carlson Capital L P now owns 510,000 shares of the specialty pharmaceutical company’s stock worth $1,550,000 after buying an additional 239,170 shares in the last quarter. DRW Securities LLC purchased a new position in Lipocine during the second quarter worth approximately $443,000. State Street Corp increased its position in Lipocine by 1,408.9% in the second quarter. State Street Corp now owns 200,679 shares of the specialty pharmaceutical company’s stock worth $609,000 after buying an additional 187,379 shares in the last quarter. BlackRock Institutional Trust Company N.A. increased its position in Lipocine by 63.2% in the second quarter. BlackRock Institutional Trust Company N.A. now owns 365,851 shares of the specialty pharmaceutical company’s stock worth $1,112,000 after buying an additional 141,681 shares in the last quarter. Finally, BlackRock Fund Advisors increased its position in Lipocine by 1,117.8% in the second quarter. BlackRock Fund Advisors now owns 433,171 shares of the specialty pharmaceutical company’s stock worth $1,317,000 after buying an additional 397,601 shares in the last quarter. Hedge funds and other institutional investors own 47.23% of the company’s stock.

Lipocine Company Profile

Lipocine Inc is a specialty pharmaceutical company. The Company is focused on applying its oral drug delivery technology for the development of pharmaceutical products in the area of men’s and women’s health. Its primary development programs are based on oral delivery solutions for bioavailable drugs.

5 Day Chart for NASDAQ:LPCN

Receive News & Stock Ratings for Lipocine Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lipocine Inc. and related stocks with our FREE daily email newsletter.